AR056748A1 - Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco - Google Patents

Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco

Info

Publication number
AR056748A1
AR056748A1 ARP060104769A ARP060104769A AR056748A1 AR 056748 A1 AR056748 A1 AR 056748A1 AR P060104769 A ARP060104769 A AR P060104769A AR P060104769 A ARP060104769 A AR P060104769A AR 056748 A1 AR056748 A1 AR 056748A1
Authority
AR
Argentina
Prior art keywords
injection
prevent
reconstitution
dilution
hemolysis
Prior art date
Application number
ARP060104769A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37801586&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056748(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR056748A1 publication Critical patent/AR056748A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion proporciona métodos para la preparacion de formulaciones farmacéuticas para inyeccion tal que en la inyeccion la formulacion no provoque la aglutinacion de eritrocitos, hemolisis, y/o contraccion de células. Para prevenir la aglutinacion, una formulacion farmacéutica preparada para inyeccion necesita tener una fuerza ionica suficiente. Para prevenir la hemolisis o la contraccion de células, una formulacion farmacéutica preparada para inyeccion necesita ser casi isotonica con respecto al plasma. La invencion proporciona métodos que preparan formulaciones farmacéuticas para inyeccion que tienen tanto la fuerza ionica suficiente para prevenir la aglutinacion y la tonicidad requerida para prevenir hemolisis o deshidratacion o contraccion de células significativas. Los métodos presentes involucran el uso de soluciones de cloruro de socio que son alredodor de 25 MM hasta alrededor de 150 mM para reconstitucion de tortas liofilizadas (u otras formulaciones farmacéuticas no líquidas) en solucion o para dilucion de soluciones de formulacion farmacéutica.
ARP060104769A 2005-11-01 2006-10-31 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco AR056748A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73222105P 2005-11-01 2005-11-01

Publications (1)

Publication Number Publication Date
AR056748A1 true AR056748A1 (es) 2007-10-24

Family

ID=37801586

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060104769A AR056748A1 (es) 2005-11-01 2006-10-31 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco
ARP180101902 AR112443A2 (es) 2005-11-01 2018-07-06 Un kit para reconstitución o dilución de un fármaco

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180101902 AR112443A2 (es) 2005-11-01 2018-07-06 Un kit para reconstitución o dilución de un fármaco

Country Status (31)

Country Link
US (4) US20070135343A1 (es)
EP (3) EP3593790A1 (es)
JP (1) JP5555425B2 (es)
KR (2) KR101126670B1 (es)
CN (1) CN101351190B (es)
AR (2) AR056748A1 (es)
AU (1) AU2006308921C1 (es)
BR (1) BRPI0618133A2 (es)
CA (1) CA2626531C (es)
CR (1) CR9958A (es)
DK (2) DK3225233T3 (es)
EC (1) ECSP088485A (es)
ES (2) ES2749574T3 (es)
FI (1) FI1942868T4 (es)
FR (1) FR20C1005I1 (es)
GT (1) GT200800037A (es)
HK (1) HK1245090B (es)
HU (4) HUE045421T2 (es)
IL (1) IL190843A (es)
LU (1) LUC00035I2 (es)
MY (1) MY184364A (es)
NO (1) NO347263B1 (es)
NZ (1) NZ567685A (es)
PE (3) PE20110803A1 (es)
PL (2) PL3225233T3 (es)
PT (2) PT1942868T (es)
RU (1) RU2432157C2 (es)
SI (2) SI3225233T1 (es)
TW (1) TWI480063B (es)
UA (1) UA97234C2 (es)
WO (1) WO2007053533A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110803A1 (es) 2005-11-01 2011-11-07 Wyeth Corp Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US8431011B2 (en) 2008-01-31 2013-04-30 Abbott Diabetes Care Inc. Method for automatically and rapidly distinguishing between control and sample solutions in a biosensor strip
CA2780554C (en) * 2009-11-17 2017-08-15 Ipsen Pharma S.A.S. Formulation for hgh and rhigf-1 combination
US10634741B2 (en) 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus
US9427186B2 (en) 2009-12-04 2016-08-30 Endomagnetics Ltd. Magnetic probe apparatus
HUE046670T2 (hu) 2010-01-15 2020-03-30 Kirin Amgen Inc Anti IL-17RA ellenanyag kiszerelés és terápiás rendek pikkelysömör kezelésére
NZ602685A (en) * 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
EA037095B1 (ru) 2010-07-09 2021-02-05 Биовератив Терапьютикс Инк. Способ лечения гемофилии в и эпизодов кровотечения
WO2014052490A1 (en) * 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
JP6351639B2 (ja) 2013-03-11 2018-07-04 エンドマグネティクス リミテッド リンパ節検出のための低浸透圧溶液
US9234877B2 (en) 2013-03-13 2016-01-12 Endomagnetics Ltd. Magnetic detector
US9239314B2 (en) 2013-03-13 2016-01-19 Endomagnetics Ltd. Magnetic detector
TWI683666B (zh) * 2013-03-15 2020-02-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
FR3005420B1 (fr) * 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
KR102385372B1 (ko) * 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. 동결건조된 ix 인자 제형
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
GB2536703B (en) * 2015-03-27 2020-12-02 Ge Healthcare Bio Sciences Ab Method for baseline correction in a chromatogram
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
EP3302338B1 (en) 2015-06-04 2020-09-30 Endomagnetics Ltd. Marker materials and forms for magnetic marker localization
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ,エルエルシー 凍結乾燥方法
JP7495426B2 (ja) 2019-03-14 2024-06-04 テルモ ビーシーティー バイオテクノロジーズ,エルエルシー 凍結乾燥容器用充填治具、システム及び使用方法
US12036187B2 (en) * 2019-05-01 2024-07-16 Southwest Research Institute Compositions of dimethyl trisulfide (DMTS) as a cyanide antidote
IL272145A (en) * 2020-01-20 2021-07-29 Stem Cell Medicine Ltd Cosmetic preparations with protein concentrate from a conditioned growth medium of stem cells from adipose tissue
AU2021322623A1 (en) * 2020-08-03 2023-03-02 Transluminal Systems, Llc Devices and methods for trans-arterial osmotic embolization of pathological tissue

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
US4364861A (en) 1980-05-27 1982-12-21 Cutter Laboratories, Inc. Blood-coagulation-promoting products and methods of preparing them
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
JP5149470B2 (ja) 1999-02-22 2013-02-20 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第viii因子処方物
US20010031721A1 (en) * 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
US6875432B2 (en) * 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
KR20150138427A (ko) * 2003-12-19 2015-12-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 vii 폴리펩티드의 안정화된 조성물
JP2007526329A (ja) * 2004-03-04 2007-09-13 ワイス 賦形剤の結晶化を改善するための凍結乾燥法
PE20110803A1 (es) 2005-11-01 2011-11-07 Wyeth Corp Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco

Also Published As

Publication number Publication date
CR9958A (es) 2008-07-29
US20170021022A1 (en) 2017-01-26
LUC00035I2 (es) 2017-12-01
PE20110803A1 (es) 2011-11-07
GT200800037A (es) 2008-10-01
CA2626531C (en) 2011-11-29
HUE045421T2 (hu) 2019-12-30
HK1245090B (zh) 2020-04-09
DK1942868T5 (da) 2024-01-08
IL190843A (en) 2013-08-29
EP3225233B1 (en) 2019-08-14
EP1942868B2 (en) 2023-10-04
US20200338199A1 (en) 2020-10-29
TW200803915A (en) 2008-01-16
EP3593790A1 (en) 2020-01-15
AU2006308921B2 (en) 2012-07-19
PT1942868T (pt) 2017-06-16
KR20080065689A (ko) 2008-07-14
DK3225233T3 (da) 2019-10-14
UA97234C2 (ru) 2012-01-25
TWI480063B (zh) 2015-04-11
FI1942868T4 (fi) 2023-10-12
KR20110128957A (ko) 2011-11-30
JP5555425B2 (ja) 2014-07-23
PT3225233T (pt) 2019-10-24
DK1942868T3 (en) 2017-06-26
ECSP088485A (es) 2008-06-30
ES2627684T3 (es) 2017-07-31
EP1942868A2 (en) 2008-07-16
KR101126670B1 (ko) 2012-04-23
PL1942868T3 (pl) 2017-09-29
ES2749574T3 (es) 2020-03-23
CN101351190A (zh) 2009-01-21
IL190843A0 (en) 2008-11-03
WO2007053533A8 (en) 2008-07-24
PL1942868T5 (pl) 2023-12-27
JP2009513705A (ja) 2009-04-02
AR112443A2 (es) 2019-10-30
EP1942868B1 (en) 2017-04-19
LUC00035I1 (es) 2017-09-28
WO2007053533A3 (en) 2007-12-06
CN101351190B (zh) 2013-01-02
PL3225233T3 (pl) 2019-12-31
HUS1700035I1 (hu) 2017-11-28
FR20C1005I1 (fr) 2020-03-20
RU2432157C2 (ru) 2011-10-27
MY184364A (en) 2021-04-01
HUE033949T2 (hu) 2018-01-29
CA2626531A1 (en) 2007-05-10
AU2006308921C1 (en) 2013-01-24
NO20082180L (no) 2008-07-04
PE20151284A1 (es) 2015-10-05
PE20070714A1 (es) 2007-07-20
AU2006308921A1 (en) 2007-05-10
NZ567685A (en) 2011-07-29
US20200138952A1 (en) 2020-05-07
NO20082180A (no) 2008-07-04
DK1942868T4 (da) 2023-11-06
BRPI0618133A2 (pt) 2011-08-16
SI3225233T1 (sl) 2019-10-30
SI1942868T1 (sl) 2017-07-31
US20070135343A1 (en) 2007-06-14
EP3225233A1 (en) 2017-10-04
RU2008119514A (ru) 2009-12-10
HUS2000003I1 (hu) 2020-02-28
SI1942868T2 (sl) 2023-12-29
ES2627684T5 (es) 2024-04-29
NO347263B1 (no) 2023-08-14
WO2007053533A2 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
AR056748A1 (es) Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
AR039688A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
DE69906084D1 (de) Ibuprofen enthaltende schnelllösliche zusammensetzungen mit analgetischer wirkung
PE20070492A1 (es) Forma cristalina delta del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
AR078885A2 (es) Composiciones estabilizadas de proteinas que tienen un radical tiol libre. recipiente impermeable. metodo.
ATE316757T1 (de) Cryokonservierung menschlicher roter blutzellen
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
AR033059A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada.
GT200600033A (es) Formulaciones liquidas estabilizadas de polipeptido
AR035786A2 (es) Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen
ECSP034613A (es) Preparacion liofilizada de pantoprazol e inyeccion de pantoprazol
IS7394A (is) Stöðugar lyfjasamsetningar
CY1106181T1 (el) Φαρμακευτικος σχηματισμος ο οποιος πepιλαμβανει γλυκινη σαν ενα σταθepοποιητη
ATE226449T1 (de) Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen
Liu et al. Cytoprotective properties of novel nonpeptide calpain inhibitors in renal cells
ES2418459R1 (es) Relacionando agregacion proteica con supervivencia de levadura
ME00088B (me) Farmaceutski preparat i njegova priprema
BR112022025192A2 (pt) Derivado de insulina asparte, e método de preparação para o mesmo e uso do mesmo
AR091707A1 (es) Formulaciones estabilizadas de etanercept
DE69927845D1 (de) Verwendung des vaskularen endothelialen wachstumsfaktors (vegf)
Pollanen et al. An investigation of orienting mechanisms of the quantum Hall stripe phases
UY37260A (es) Formulación de neurotoxina que comprende un tensioactivo, un aminoácido seleccionado de triptófano o tirosina, y un tampón
TH125812B (th) องค์ประกอบสารเสริมซึ่งประกอบรวมด้วยสารไอโซโทนิกที่ไม่เป็นไอออนิก
Tao et al. THE FAUNA AND GE0GRAPHICAL DIVISI0N 0N GLIRES 0F GANSU PR0VINCE

Legal Events

Date Code Title Description
FC Refusal